Phosphatidylserine and Childhood Attention: What the Small-Trial Evidence Actually Shows

Scroll through any parenting forum about ADHD and you'll find phosphatidylserine (PS) mentioned constantly. It's sold as a "brain phospholipid," it sounds scientific, and supplement companies lean hard on the word natural. But what does the actual clinical research in children show? The honest answer is: a handful of small, genuinely interesting trials, at least one negative result in a specific population, and a long list of things we still don't know. Here's how to read that evidence clearly.

What Phosphatidylserine Actually Is

PS is a phospholipid—a fat molecule with a phosphate head—found in every cell membrane in your body. It is particularly concentrated in brain tissue. At the cellular level, PS plays housekeeping roles in membrane structure and cell-signaling; it is not sitting inert in the bilayer but actively moves between membrane layers in response to physiological events (Kay et al., Molecular Biology of the Cell, 2012). Human breast milk contains PS as a component of milk fat globule membranes, structures that carry bioactive lipids relevant to early neurodevelopment (Maheshwari et al., Newborn, 2024). That biological plausibility—PS is a real brain nutrient, not an invented one—is part of why researchers started asking whether supplementing it could help children with attention difficulties.

What the Positive Trials Found

The most frequently cited pediatric trial is a 2013 randomized double-blind placebo-controlled study by Hirayama and colleagues. Thirty-six drug-naïve children aged 4–14 with ADHD symptoms received either 200 mg/day of soy-derived PS or placebo for two months. Children in the PS group showed statistically significant improvements in ADHD symptom scores (p < 0.01), short-term auditory memory on the Digit Span test (p < 0.05), and measures of inattention and impulsivity on a visual GO/NO-GO task (p < 0.05). No adverse effects were reported (Hirayama et al., Journal of Human Nutrition and Dietetics, 2014). Those are real numbers from a real RCT.

More recently, a 2025 randomized controlled trial by Friling and colleagues examined sunflower-derived PS specifically in healthy children aged 8–12 who did not have an ADHD diagnosis. The trial reported cognitive effects from supplementation in this neurotypical population (Friling et al., Nutrition Journal, 2025). This is relevant because it suggests PS effects may not be limited to children who already meet diagnostic criteria—though whether that matters clinically for healthy kids remains an open question.

What the Negative and Null Results Show

Here is where the picture gets genuinely complicated—and where supplement marketing almost never goes.

A multicenter French RCT by Rheims and colleagues enrolled children aged 6–16 who had both epilepsy and ADHD. Participants received either PS enriched with omega-3 polyunsaturated fatty acids (PS-Omega3) or placebo for 12 weeks, followed by a 12-week open-label extension. The reduction in the ADHD inattention subscore after 12 weeks was −1.57 in the PS-Omega3 group and −2.90 in the placebo group—actually numerically better for placebo, though the difference was not statistically significant (p = 0.33). No secondary ADHD outcomes differed between groups. The authors concluded their data "strongly suggested" the PS-Omega3 formulation did not improve ADHD symptoms in this population, though the trial was underpowered due to early termination from enrollment difficulties (Rheims et al., Epilepsia Open, 2024).

Two critical caveats apply here. First, the epilepsy comorbidity may make this population genuinely different from children with ADHD alone—PS effects on attention could plausibly be modified by anticonvulsant medications or by the neurological substrate of epilepsy. Second, underpowered trials cannot rule out effects. But the null result still matters: it shows PS is not a guaranteed win, and that population and formulation details change outcomes.

Where the Broader Evidence Stands

A 2021 systematic review and meta-analysis by Bruton and colleagues specifically examined PS for pediatric ADHD, pooling multiple trials (Bruton et al., Journal of Alternative and Complementary Medicine, 2021). Their work provides the most comprehensive synthesis of this specific literature available so far.

A 2024 network meta-analysis by Zhou and colleagues compared 12 antioxidant and nutritional interventions across 48 studies in 3,650 children and adolescents with ADHD. In their analysis, PS ranked as the optimal agent for improving attention on the ADHD Rating Scale–Parent (SUCRA 0.39) and the overall total score (SUCRA 0.34); the PS+omega-3 combination ranked highly on teacher-rated hyperactivity outcomes. However, the authors were explicit: "Due to the low methodological quality of the included studies, the probability ranking cannot fully explain the clinical efficacy, and the results need to be interpreted with caution." More high-quality studies are still needed (Zhou et al., PLOS One, 2024). That caveat is not boilerplate. It reflects genuine limitations in sample sizes, blinding, outcome standardization, and follow-up duration across virtually all the included trials.

What Parents Should Realistically Take From This

A few things are reasonably well-supported by the available evidence:

PS is generally well-tolerated in children at doses used in trials (around 200 mg/day). The Hirayama trial reported no adverse effects (Hirayama et al., Journal of Human Nutrition and Dietetics, 2014).
Some children in controlled trials have shown measurable improvements in attention and short-term memory. These are not fabricated findings.
PS is not a substitute for established ADHD treatments. None of the trials reviewed here were designed to compare PS against stimulant medication; the network meta-analysis included it alongside other antioxidants in a supplementary context (Zhou et al., PLOS One, 2024).
Formulation matters. The soy-derived PS in the Hirayama trial, the sunflower-derived PS in the Friling trial, and the PS-Omega3 combination in the Rheims trial are not interchangeable products. Different sources and cofactors may produce different results.
Children with neurological comorbidities represent a distinct population. The negative Rheims trial enrolled children with epilepsy, and its null results should not be assumed to apply to children with ADHD alone—but they also cannot be ignored (Rheims et al., Epilepsia Open, 2024).

The practical bottom line: PS has biologically plausible mechanisms, some genuine positive trial data, and a safety profile that looks reasonable. It does not have the large, rigorously replicated evidence base you'd want before calling it a reliable treatment. If you're considering it, discuss it with your child's pediatrician or developmental specialist before starting—not because it's dangerous, but because that conversation will help you set realistic expectations, account for your child's specific situation, and keep it in its proper place within a broader care plan.

At Avaneuro, we're committed to translating real research for real families. If you found this useful, explore our other deep-dives on pediatric nutrition and neurodevelopment.

References

Zhou, P., et al. (2024). Safety and efficacy of antioxidant therapy in children and adolescents with attention deficit hyperactivity disorder: A systematic review and network meta-analysis. PloS One. https://pubmed.ncbi.nlm.nih.gov/38547138/
Hirayama, S., et al. (2014). The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. Journal of Human Nutrition and Dietetics. https://pubmed.ncbi.nlm.nih.gov/23495677/
Maheshwari, A., et al. (2024). Milk Fat Globules: 2024 Updates. Newborn (Clarksville, Md.). https://pubmed.ncbi.nlm.nih.gov/39474586/
Rheims, S., et al. (2024). Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial. Epilepsia Open. https://pubmed.ncbi.nlm.nih.gov/38173190/
Bruton, A., et al. (2021). Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. Journal of Alternative and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/33539192/
Kay, J. G., et al. (2012). Phosphatidylserine dynamics in cellular membranes. Molecular Biology of the Cell. https://pubmed.ncbi.nlm.nih.gov/22496416/
Friling, R., et al. (2025). The cognitive effects of supplementation with sunflower phosphatidyl serine in healthy children aged 8 to 12 years: a randomized controlled trial. Nutrition Journal. https://pubmed.ncbi.nlm.nih.gov/41318468/